Merck & Co., Inc. (NYSE:MRK) Research Coverage Started at Svb Leerink

Svb Leerink assumed coverage on shares of Merck & Co., Inc. (NYSE:MRK) in a research report sent to investors on Friday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $103.00 price target on the stock. Svb Leerink also issued estimates for Merck & Co., Inc.’s Q3 2019 earnings at $1.24 EPS, Q4 2019 earnings at $1.17 EPS and FY2023 earnings at $6.33 EPS.

MRK has been the topic of a number of other research reports. Citigroup lifted their target price on Merck & Co., Inc. from $84.00 to $95.00 and gave the company a buy rating in a research report on Friday, June 21st. They noted that the move was a valuation call. Credit Suisse Group restated a buy rating and issued a $95.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, August 7th. ValuEngine downgraded Merck & Co., Inc. from a buy rating to a hold rating in a research report on Thursday, August 1st. JPMorgan Chase & Co. lifted their price objective on Merck & Co., Inc. from $90.00 to $93.00 and gave the company an overweight rating in a research note on Friday, June 14th. Finally, UBS Group lifted their price objective on Merck & Co., Inc. from $87.00 to $88.00 and gave the company a buy rating in a research note on Thursday, May 2nd. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Merck & Co., Inc. presently has an average rating of Buy and an average price target of $92.56.

NYSE:MRK opened at $85.06 on Friday. Merck & Co., Inc. has a 52 week low of $66.10 and a 52 week high of $87.07. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $213.69 billion, a P/E ratio of 19.60, a P/E/G ratio of 1.70 and a beta of 0.56. The stock’s fifty day moving average is $83.38 and its two-hundred day moving average is $80.94.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The company had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $10.94 billion. During the same quarter in the previous year, the business earned $1.06 earnings per share. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. Sell-side analysts anticipate that Merck & Co., Inc. will post 4.91 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $2.20 annualized dividend and a yield of 2.59%. Merck & Co., Inc.’s payout ratio is 50.69%.

In related news, EVP Richard R. Deluca sold 6,427 shares of the business’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the transaction, the executive vice president now directly owns 103,223 shares of the company’s stock, valued at approximately $8,783,245.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert M. Davis sold 216,718 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $85.43, for a total value of $18,514,218.74. Following the transaction, the chief financial officer now directly owns 354,378 shares of the company’s stock, valued at $30,274,512.54. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Titan Capital Management LLC CA purchased a new stake in Merck & Co., Inc. during the 2nd quarter valued at approximately $25,000. LFA Lugano Financial Advisors SA raised its stake in Merck & Co., Inc. by 250.0% during the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock valued at $26,000 after acquiring an additional 225 shares during the last quarter. JJJ Advisors Inc. purchased a new stake in Merck & Co., Inc. during the 2nd quarter valued at approximately $27,000. Cumberland Partners Ltd purchased a new stake in Merck & Co., Inc. during the 2nd quarter valued at approximately $40,000. Finally, PRW Wealth Management LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at approximately $41,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: Moving Average (MA)

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.